[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644514":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":22,"locations":10,"responsibleParty":28,"collaborators":10,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":10,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":10,"enrollmentInfo":41,"targetDuration":10,"studyType":44,"phases":10,"briefSummary":45,"conditions":46,"keywords":10,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"Tianjin Medical University Cancer Institute and Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Low expression of HER2",null,"Patients with low HER2 expression (IHC 1+ or IHC 2+\u002FISH-) and HER2 IHC 0 advanced breast cancer",[13],"Drug: Anti-HER2-ADC drug Deruxtepracabine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Anti-HER2-ADC drug Deruxtepracabine","By monitoring the levels of CTCs\u002FCTECs and serum HER2 expression in breast cancer patients receiving anti-HER2-ADC treatment during the treatment process, we aim to determine the therapeutic monitoring value of CTCs\u002FCTECs and serum HER2 in these breast cancer patients using anti-HER2-ADC drugs.",[9],[21],"Other medications: The doctor will determine the administration plan based on the specific circumstances.",[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Yehui Shi Yehui Shi, Doctor of Medicine","CONTACT","+8618622221183","shiyehui@tjmuch.com",{"type":29,"investigatorFullName":30,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Yehui Shi","Chief Physician","100644514","the-efficacy-of-combined-peripheral-blood-ctcs-and-serum-her2-detection-in-docetaxel-based-treatment-for-her2-low-expression-breast-cancer-100644514",false,"NCT07670182","The Efficacy of Combined Peripheral Blood CTCs and Serum HER2 Detection in Docetaxel-based Treatment for HER2 Low-expression Breast Cancer","A Prospective, Multicenter Clinical Study on the Efficacy Correlation of Deruxtepruzumab Treatment for Advanced Breast Cancer With Low\u002FUltra-low HER2 Expression, Guided by Peripheral Blood CTCs\u002FCTECs Combined With Serum HER2 Detection","Inclusion Criteria:\n\n1. Patients with a pathological record of breast cancer;\n2. Group A: Diagnosed with low expression of HER2 (IHC 1+ or IHC 2+ and ISH-); Group B: Diagnosed with HER2 0 expression (IHC 0);\n3. No history of other malignant tumors;\n4. Signed the informed consent form at the age of 18 or above;\n5. Possess relatively complete clinical case characteristic data.\n\nExclusion Criteria:\n\n* 1\\. Male breast cancer patients; 2. Pregnant or breastfeeding; 3. Patients known to have an allergic reaction to the active substances or any excipients of T-DXd; 4. Patients judged by the investigators to be unsuitable to participate in this study.","FEMALE","18 Years",{"count":42,"type":43},100,"ESTIMATED","OBSERVATIONAL","This study is a multicenter, double-cohort clinical research aimed at systematically evaluating the value of jointly detecting the HER2 expression of CTCs\u002FCTECs and the serum HER2 ECD level in predicting the efficacy of T-DXd treatment for patients with HER2 low expression (IHC 1+ or IHC 2+\u002FISH-) and HER2 IHC 0 advanced breast cancer.",[47],"Patients With Low HER2 Expression (IHC 1+ or IHC 2+\u002FISH-) and HER2 IHC 0 Advanced Breast Cancer","NOT_YET_RECRUITING","2026-06-24",{"date":51,"type":52},"2026-06-26","ACTUAL",{"date":54,"type":43},"2026-06-15",{"date":56,"type":43},"2031-01-01",{"name":5,"class":6}]